TheraVet, a leading company specializing in osteoarticular treatments for pets, is making waves in the highly competitive field of equine competition horses. With the recent launch of their BIOCERA-VET® Equine range, TheraVet aims to position itself as the go-to provider for osteoarticular disease treatments in the global population of 12 million competition horses.
Equine competition is not only a thrilling sport but also a significant part of the massive $402 billion sport betting market. TheraVet recognizes the immense potential in this market and aims to become the industry leader in treating the main indications affecting competition horses.
The BIOCERA-VET® Equine range, along with the upcoming VISCO-VET® program, offers groundbreaking therapeutic solutions for performance horses. One notable treatment is the minimally invasive treatment of subchondral bone cysts, a common issue that negatively impacts performance and auction prices. By providing properties required for cementoplasty, such as high injectability and fast self-setting, BIOCERA-VET® Equine enables effective treatment and improved performance for these horses.
TheraVet is dedicated to ongoing clinical evaluations in collaboration with specialist equine orthopedic surgeons. These evaluations aim to solidify BIOCERA-VET®’s position as the preferred treatment option for equine bone cysts, osteoarticular diseases, and dental problems affecting competition horses.
Looking to the future, TheraVet has ambitious plans to expand its range of products for competition horses. By 2027, they plan to launch BIOCERA-VET® OSTEO, which boasts enhanced osteo-inductive properties, NUTRA-VET®, a range of high-performance nutraceuticals, and VISCO-VET® Equine, a visco-regenerating gel for treating osteoarticular diseases and tendon and ligament injuries.
Through their innovative treatments and strategic partnerships, TheraVet strives to improve the quality of life for companion animals, including equine athletes. As a listed company on Euronext Growth® Paris and Brussels, TheraVet continues to lead the way in veterinary biotechnology, revolutionizing the equine industry one treatment at a time.
For more information about TheraVet and their range of products, visit their website or follow them on LinkedIn and Facebook.
The article discusses TheraVet, a leading company specializing in osteoarticular treatments for pets, and its recent launch of the BIOCERA-VET® Equine range, which aims to provide innovative therapeutic solutions for competition horses. However, there are several additional facts and information that can be added to enhance the discussion.
One important aspect to discuss is the current market trends in the equine industry. The global equine industry is experiencing significant growth, with the sport of equine competition and betting market contributing to its success. The article mentions that the sport betting market is valued at $402 billion, highlighting the immense potential in this industry.
Furthermore, it would be valuable to provide forecasts regarding the market size and growth rate of the equine industry, particularly the segment related to competition horses. Industry reports and studies could be referenced to provide insights on the expected growth trajectory and market opportunities.
Discussing the advantages and disadvantages of the BIOCERA-VET® Equine range would give a more comprehensive understanding of the product. Advantages can include the groundbreaking nature of the range and its ability to effectively treat common issues such as subchondral bone cysts. The article mentions that the treatment provides properties required for cementoplasty, offering high injectability and fast self-setting, leading to improved performance for horses.
Key challenges or controversies associated with the use of therapeutic solutions for competition horses should also be addressed. Some potential challenges could include the cost of treatment, access to specialized veterinary care, and any potential side effects or risks associated with the use of the products.
In terms of future plans, the article briefly mentions that TheraVet has ambitious plans to expand its range of products for competition horses. It would be beneficial to delve deeper into these plans and discuss how they will further revolutionize the equine industry. This can include discussing the potential impact of the planned launch of BIOCERA-VET® OSTEO, NUTRA-VET®, and VISCO-VET® Equine on the market and the benefits they may provide.
To provide reliable and trustworthy information, suggested related links could be included. For example, linking to industry reports, market analysis articles, or scientific studies that support the points discussed in the article. However, as an AI assistant, I cannot provide real-time links as they may become outdated.